Skip to main content
XTL Biopharmaceuticals Ltd. logo

XTL Biopharmaceuticals Ltd. — Investor Relations & Filings

Ticker · XTLB ISIN · IL0010854979 LEI · 529900NDDXEAPTUTXP41 TA Manufacturing
Open in API
Filings indexed 1,223 across all filing types
Latest filing 2016-09-27 Interim / Quarterly Rep…
Country IL Israel
Listing TA XTLB

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Recent filings

Filing Released Lang Actions
Immediate Report
Interim / Quarterly Report Classification · 100% confidence The document is a Form 6-K filed with the SEC by XTL Biopharmaceuticals Ltd. It contains the company's financial results for the second quarter of 2016, including consolidated statements of financial position and comprehensive loss. Because it provides substantive financial data and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report (IR). Q2 2016
2016-09-27 English
Immediate Report
Report Publication Announcement Classification · 98% confidence The document is an 'Immediate Report' filed with the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE). It explicitly states: 'Attached hereto is a report on *SECOND QUARTER 2016 FINANCIAL RESULTS & CLINICAL AND OPERATIONAL UPDATE*'. The document itself is very short (1855 characters) and serves primarily to announce the availability of the actual financial report, rather than containing the full financial data. This structure strongly indicates a Report Publication Announcement (RPA), as per the 'MENU VS MEAL' rule, because it announces the publication of a specific report (Second Quarter 2016 Financial Results). While it relates to quarterly results, the primary function of this specific filing is the announcement itself.
2016-09-27 English
FORM 6-K
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, XTL Biopharmaceuticals Ltd., with the SEC. It references unaudited interim condensed consolidated financial statements as of June 30, 2016, and an Operating and Financial Review and Prospects for the same period. Form 6-K is typically used to report interim or other periodic financial information by foreign private issuers. The document length is 2083 characters, which is relatively short and mainly serves as a report submission rather than a full detailed report. However, it includes actual financial statements and operating review data for an interim period, indicating it is an interim or quarterly report rather than just an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2016-09-27 English
FORM 6-K
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, XTL Biopharmaceuticals Ltd., reporting financial results for the second quarter of 2016 and providing clinical and operational updates. It includes detailed financial data such as cash balances, expenses, operating loss, and comprehensive loss for the quarter and six months ended June 30, 2016. The presence of unaudited financial statements and comprehensive financial data for a quarterly period indicates this is an interim or quarterly report. The document is not an annual report (10-K), nor is it a simple announcement or certification. It is a comprehensive financial report for a period shorter than a full fiscal year, consistent with the definition of an Interim / Quarterly Report (IR).
2016-09-27 English
Immediate Report
Regulatory Filings Classification · 95% confidence The document is explicitly titled 'Form 6-K' and is filed 'Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934' by a 'Foreign Private Issuer'. Form 6-K is a required filing for foreign private issuers to report material information that is made public in their home country or stock exchange, or that is required to be filed with a foreign securities commission. This type of filing does not map directly to the standard US periodic reports (like 10-K or 10-Q) or specific event filings (like DEF 14A or 8-K). Among the provided categories, 'Regulatory Filings' (RNS) is the most appropriate general category for miscellaneous, non-standard SEC filings like Form 6-K, especially when the content is a press release announcing a patent grant, which is not covered by other specific codes (like ER, CAP, or LTR). Although it contains press release content, the primary wrapper is the SEC Form 6-K.
2016-09-07 English
Immediate Report
Report Publication Announcement Classification · 98% confidence The document is an 'Immediate Report' filed with the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE). It explicitly states: 'Attached hereto is a report on *patent grant by the European Patent Office (EPO) for the Company’s lupus drug candidate, hCDR1.*' The document itself is very short (1865 characters) and its primary function is to announce the publication of an attached report (the patent grant information). According to Rule 2, when a document is short and announces that a report is attached or published, it should be classified as a Report Publication Announcement (RPA). It is not the full financial report (10-K, IR) or a specific legal filing like LTR, but rather an announcement about a specific event/document release.
2016-09-07 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.